Spectroscopic whole-blood indicators of end-stage renal disease and the hemodialysis treatment.
The diffuse reflection spectrum in the 500-1670 nm region for whole blood taken from healthy subjects and end-stage renal disease (ESRD) patients was measured to test the feasibility of optically monitoring ESRD and its treatment by hemodialysis. Spectral regions where optical absorption significantly differed between healthy subjects and ESRD patients were used to form a multiple linear discriminant classification model. With this model a total of 41 whole-blood samples were classified into healthy, pretreatment and posttreatment ESRD classes. 96.7% of original and cross-validated cases and 100% of independent validation cases were correctly classified, indicating ESRD and its treatment exhibit characteristic spectral features in whole blood. Upon comparison of the discriminant model variables with a few key clinical blood parameters, model variables were found to significantly correlate with hematocrit and plasma levels of urea and potassium (P<0.05). The results of this study suggest that the optical signature of whole blood conveys basic clinical status information, and provides a path for investigating improved indices of hemodialysis toxicity, adequacy and patient outcome.